Skip to content
Twitter Facebook-f Youtube Instagram Linkedin
NETs Info
Donate
Close Menu
  • Who We Are
    • About Us
    • Our People
    • Our Board
    • Our Ambassadors
    • Consumer Advisory Group
    • International Advisory Panel
    • Governance & Policy
  • Neuroendocrine Cancers
    • What are Neuroendocrine Cancers?
    • Patient Resources
    • Pheos and Paras
    • NET Library
  • Optimal Care Pathway
    • For Patients
    • For Health Professionals
  • I Am a Patient
    • Patient Support
    • Patient Resources
    • NET Nurse
    • Patient Stories
    • Australian NET Specialists
    • Current Clinical Trials
  • I am a HCP
    • Professional Learning
    • HCP – Patient Referral to NET Nurse
    • Current Clinical Trials
    • NET Library
    • HCP Newsletter & Signup
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order booklets and other resources
  • Get Involved
    • Advocate for us
    • Share your story
    • Donate
    • Fundraise
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Workplace Giving
    • Volunteer
  • What’s On
    • News
    • Newsletter & Signup
    • INCA Newsletter archive
    • Events
  • Shop
  • Contact Us
Donate
  • Who We Are
    • About Us
    • Our People
    • Our Board
    • Our Ambassadors
    • Consumer Advisory Group
    • International Advisory Panel
    • Governance & Policy
  • Neuroendocrine Cancers
    • What are Neuroendocrine Cancers?
    • Patient Resources
    • Pheos and Paras
    • NET Library
  • Optimal Care Pathway
    • For Patients
    • For Health Professionals
  • I Am a Patient
    • Patient Support
    • Patient Resources
    • NET Nurse
    • Patient Stories
    • Australian NET Specialists
    • Current Clinical Trials
  • I am a HCP
    • Professional Learning
    • HCP – Patient Referral to NET Nurse
    • Current Clinical Trials
    • NET Library
    • HCP Newsletter & Signup
    • Australian NET Specialists
    • Request an In-Service
    • PLANET Registry
    • Order booklets and other resources
  • Get Involved
    • Advocate for us
    • Share your story
    • Donate
    • Fundraise
    • In Memoriam
    • Corporate Partners
    • Gifts & Wills
    • Workplace Giving
    • Volunteer
  • What’s On
    • News
    • Newsletter & Signup
    • INCA Newsletter archive
    • Events
  • Shop
  • Contact Us

Home » Advocacy » Unicorn Foundation – Japan HTAi 2016

Unicorn Foundation – Japan HTAi 2016

  • May 30, 2016
Health Technology Assessment international (HTAi) is an international society for the promotion of Health Technology Assessment. HTA in Australia includes the Therapeutic Goods Administration (TGA) and Pharmaceutical Benefits Scheme (PBS), which assess new drugs for their effectiveness and ultimately access to patients.

Unicorn Foundation CEO, Simone Leyden was asked to present the Australian landscape, at the pre-conference workshop "East Meets West: What we can learn from each other about Patient Perspectives and adding value to HTA". This was an invaluable meeting as we heard from speakers from NICE (National Institute for Health and Care Excellence) UK, CADTH (Canadian Agency for Drugs and Technologies in Health), Taiwan, Japan, and the Netherlands. Results from a survey of 15 patient groups across 10 countries were presented by Janney Wale which sought to find answers to "How patient groups see their involvement in HTA". There was a wealth of information presented covering the how, what, when and why of patient input into the assessment of technologies which formed a great basis for ongoing talk over the conference. 

                 

We thank Janney Wale the outgoing President and the incoming President Neil Bertelsen of the Patient and Citizen Involvement HTAi Special Interest Group for a great workshop to kick start the conference. 

Thanks to Dr Karen Facey for organising the Unicorn Foundation to attend as one of three patient organisations at a lunchtime discussion with representatives from the FDA (Federal Drug Administration – USA), EMA (European Medicines Agency) and HAS (Haute Autorité de Santé – France). It was a robust discussion around multi-stakeholder approaches to improve evidence based decisions in rare diseases and each patient representative was able to present a case study (UF – CONTROL NETs Trial). Everyone was in agreeance that when it came to drug access for rare, there needs to be a different approach to gathering "Real World Evidence", trial design, label extension, the repurposing of drugs and the need for adaptive decision making. A lot of food for thought when approaching our own decision makers. 

The final report from this round table discussion can be found below for download. 

https://neuroendocrine.org.au/wp-content/uploads/2020/03/HTAi-2016-Panel-Report-final-for-web.pdf 

Simone has been appointed with patient representatives from the Netherlands, Japan, Taiwan and the UK to the newly formed Patient Panel, which will look further at how the consumer voice can be heard by decision makers in HTA. 

The full programme can be found here

We would like to thank the HTAi Secretariat for the travel grant we received to attend this fantastic meeting.

 

.

Share this post

Subscribe to our eNews

Stay up to date on news and events, clinical trials and new research on neuroendocrine cancers.

Recent posts

ENETS Conference 2023

March 27, 2023

Michael Doyle Live Wake Fundraiser

February 4, 2023

Optimal Care Pathway now available for NETs

January 31, 2023

World Cancer Day 2023

January 10, 2023
Categories
  • Advocacy
  • Awareness
  • Community Events
  • Education
  • Events
  • Fundraising
  • General
  • In The Media
  • News
  • Research
  • Unicorn Events
PrevPreviousHelp us improve our Support Groups
Next“Let’s Talk About NETs” this World NET Cancer Day Nov 10Next

Related Posts

Michael Doyle Live Wake Fundraiser

On Saturday February 4th our Consumer Advisory Group member for Western Australia, Michael Doyle not only celebrated his 65th birthday but also held a “live

World Cancer Day 2023

World Cancer Day: a leading international awareness day to “Close the Care Gap” World Cancer Day held on 4 February every year is the global

NeuroEndocrine Cancer Australia & Norman Family Trust Partnership

NeuroEndocrine Cancer Australia are delighted to announce a new donor partnership. The Norman Family Bequest are funding a NET Nurse Educator in memory of Will

NeuroEndocrine Cancer Australia partners with Gathered Here to provide the NET community with free online Wills

NeuroEndocrine Cancer Australia have partnered with Gathered Here, Australia’s most-trusted end-of-life services site, to offer our supporters a free online will. We are constantly looking

View All

Make a difference

How much do you wish to donate?
$50
$100
$250
$500
$1000
Other
NeuroEndocrine Cancer Australia logo white
Twitter Facebook-f Youtube Instagram Linkedin

All donations are tax deductible.
Registered Charity CFN 202607

Who We Are

  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies
  • About Us
  • Our People
  • Our Ambassadors
  • Consumer Advisory Group
  • International Advisory Panel
  • Governance & Policies

Neuroendocrine Cancers

  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library
  • What are Neuroendocrine Cancers?​
  • Pheos and Paras
  • NET Library

For Patients

  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials
  • Patient resources
  • NET Nurse
  • Patient Stories
  • Australian NET Specialists
  • Current Open Clinical Trials

Get Involved

  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise
  • Shop
  • Donate
  • Volunteer
  • Current Fundraising Campaigns
  • Fundraise

© 2020 NeuroEndocrine Cancer Australia

  • Website by Five Creative